Corvus Pharmaceuticals Inc (CRVS) Stock Analysis

Corvus Pharmaceuticals Inc (CRVS) is a publicly traded company in the HEALTHCARE sector. It trades at $11.69, carries a market capitalization of $1.02B. This page summarizes the public market data, fundamentals, and frequently asked questions for CRVS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Corvus Pharmaceuticals Inc currently has a Neutral sentiment score of -0.01.

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Burlingame, California, specializing in the development of innovative immuno-oncology therapies targeting multiple cancers. The company is advancing a robust pipeline of proprietary drug candidates designed to optimize immune system responses and enhance patient outcomes through precision medicine. By fostering strategic partnerships and leveraging cutting-edge research, Corvus is actively contributing...

GNG Research Analysis

GNG Research scores Corvus Pharmaceuticals Inc (CRVS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CRVS.

Frequently Asked Questions

Does CRVS pay dividends?

Corvus Pharmaceuticals Inc (CRVS) does not currently pay a regular dividend.

What is CRVS's market cap?

Corvus Pharmaceuticals Inc (CRVS) has a market capitalization of $1.02B with a current stock price of $11.69.